Tuesday, September 29, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchtirzepatidenicotineaddictionpreclinical

Tirzepatide blunts nicotine reward and accumbal dopamine in male mice

The dual GIP/GLP-1 agonist also suppressed reinstatement of nicotine place preference and prevented expression of locomotor sensitisation, per British Journal of Pharmacology.

PR
By Priya Raman · Science Reporter
Sep 27 20:00 ETSource: British journal of pharmacology

The wire

  1. 01In male mice, tirzepatide dose-dependently attenuated nicotine-induced locomotor stimulation, reduced conditioned place preference and lowered nicotine-induced dopamine release in the nucleus accumbens.
  2. 02Adds incretin agonists to the list of candidates being explored for nicotine dependence, where relapse and post-cessation weight gain remain barriers.
  3. 03Animal study in male mice only, with no human data on smoking cessation; effects on GABA and other transmitters were region-specific and mechanistically unresolved.

From the source

The dual incretin agonist tirzepatide blunts nicotine-induced behaviours and neurochemistry in male mice

British journal of pharmacology · 2026 Sep 28 · Edvardsson CE, Emous TA, Witley S et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →